Trading Report: Today, Cornerstone Financial Partners LLC invests in 1,172 by purchasing Johnson & Johnson (JNJ) shares

Today, Cornerstone Financial Partners LLC invests in 1,172 by purchasing Johnson & Johnson (JNJ) shares

Cornerstone Financial Partners LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 47.1% during the second quarter, Holdings Channel reports. The firm owned 3,660 shares of the company’s stock after buying an additional 1,172 shares during the period. Cornerstone Financial Partners LLC’s holdings in Johnson & Johnson were worth $443,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in JNJ. Boston Advisors LLC boosted its position in shares of Johnson & Johnson by 388.3% in the first quarter. Boston Advisors LLC now owns 318,559 shares of the company’s stock valued at $34,468,000 after buying an additional 253,320 shares during the period. Hutner Daniel Ellsworth boosted its position in shares of Johnson & Johnson by 0.7% in the first quarter. Hutner Daniel Ellsworth now owns 60,112 shares of the company’s stock valued at $6,504,000 after buying an additional 390 shares during the period. Narwhal Capital Management boosted its position in shares of Johnson & Johnson by 1.7% in the first quarter. Narwhal Capital Management now owns 42,832 shares of the company’s stock valued at $4,634,000 after buying an additional 730 shares during the period. Handelsinvest Investeringsforvaltning boosted its position in shares of Johnson & Johnson by 20.7% in the first quarter. Handelsinvest Investeringsforvaltning now owns 40,800 shares of the company’s stock valued at $4,415,000 after buying an additional 7,000 shares during the period. Finally, Kelman Lazarov Inc. bought a new position in shares of Johnson & Johnson during the first quarter valued at $955,000. Institutional investors own 65.32% of the company’s stock.

Johnson & Johnson (NYSE:JNJ) traded down 2.15% during mid-day trading on Tuesday, hitting $115.94. The company had a trading volume of 5,831,859 shares. Johnson & Johnson has a 1-year low of $94.28 and a 1-year high of $126.07. The firm has a market capitalization of $317.20 billion, a PE ratio of 21.61 and a beta of 0.62. The company has a 50 day moving average of $118.71 and a 200 day moving average of $117.56.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 18th. The company reported $1.68 EPS for the quarter, topping the consensus estimate of $1.65 by $0.03. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. The firm had revenue of $17.80 billion for the quarter, compared to analyst estimates of $17.71 billion. During the same period in the prior year, the business posted $1.49 EPS. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. Analysts predict that Johnson & Johnson will post $6.69 earnings per share for the current fiscal year.

Several equities analysts recently commented on the company. RBC Capital Markets restated an “outperform” rating and set a $133.00 target price (up from $125.00) on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Leerink Swann restated an “outperform” rating and set a $140.00 target price (up from $125.00) on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Royal Bank Of Canada boosted their target price on Johnson & Johnson from $125.00 to $133.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 20th. BMO Capital Markets restated an “outperform” rating and set a $132.00 target price on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Finally, Deutsche Bank AG restated a “hold” rating and set a $142.00 target price (up from $125.00) on shares of Johnson & Johnson in a research report on Thursday, July 21st. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $120.20.

In other news, VP Dominic J. Caruso sold 41,146 shares of the company’s stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total value of $5,143,661.46. Following the transaction, the vice president now directly owns 157,819 shares in the company, valued at approximately $19,728,953.19. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Ronald A. Kapusta sold 2,935 shares of the company’s stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the completion of the transaction, the chief accounting officer now owns 28,660 shares in the company, valued at $3,582,786.60. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Related posts

Leave a Comment